Ocular Hypertension clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, not yet accepting patients
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
San Francisco, California
Our lead scientists for Ocular Hypertension research studies include Julius Oatts, MD.